Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

Robert A. Hauser, Laurence Salin, Nolwenn Juhel, Victor L. Konyago, Carmel Armon, Danny Bartel, Nicolaas I. Bohnen, Bruce Cleeremans, Cynthia Comella, Warren Davidson, J. Antonnelle De Marcaida, Anthony Dowel, Edward Drasby, Bradley Evans, Enrico Fazzini, Gerald Ferencz, Hubert Fernandez, Jeffrey Friedlander, Susanne Gazda, Mark GuttmanDavid Hart, Stuart Isaacson, Alan Jacobs, Joseph Jankovic, Danna Jennings, David King, Louis C. Kirby, Bruce Kohrman, Sandra Kostyk, Michael R. Liebowitz, Michael Lobatz, David Ira Margolin, Ekaterini Markopoulou, John M. Murphy, W. Alvin McElveen, Chi Kin Ng, Margarita Nunez, Sotiriof A. Parashos, John Porter, Emmanuelle Pourcher, Ali Rajput, Ralph Richter, David B. Ross, Harvey D. Schwartz, Carlos Singer, James Stevens, Jon Stoessl, Oksana Suchowersky, James P. Sutton, Mutaz Tabbaa, Daniel Truong, Paul Tuite, Roil I.Ann Wallis, Jeannette Wendt, Theresa Zesiewicz, Richard Zweig

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)359-365
Number of pages7
JournalMovement Disorders
Volume22
Issue number3
DOIs
StatePublished - Feb 15 2007

ASJC Scopus Subject Areas

  • Neurology
  • Clinical Neurology

Keywords

  • Clinical trial
  • Dopamine reuptake inhibitor
  • Dopamine transporter
  • Monotherapy
  • NS 2330
  • Parkinson's disease
  • Tesofensine
  • Treatment

Cite this